Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
GHDX > SEC Filings for GHDX > Form 8-K on 26-Nov-2013All Recent SEC Filings

Show all filings for GENOMIC HEALTH INC | Request a Trial to NEW EDGAR Online Pro

Form 8-K for GENOMIC HEALTH INC


26-Nov-2013

Other Events


Item 8.01 Other Events.

On November 25, 2013, Genomic Health, Inc. ("Genomic Health") issued a press release announcing that it has entered into an exclusive agreement with the Almac Group Ltd ("Almac") to license Almac's technology and intellectual property to develop and commercialize a test to predict benefit from DNA damage-based chemotherapy drugs, such as anthracycline-based regimens, in high risk breast cancer. Genomic Health made an up-front payment of $9 million dollars, which it expects to expense in the fourth quarter of 2013, and will pay additional milestones as certain clinical and commercial endpoints are achieved in the future. With successful commercialization of the test, Genomic Health will pay additional royalties to Almac.

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Genomic Health's plans to develop and validate a test for prediction of benefit from DNA damage-based regimens, including anthracycline, for breast cancer patients; Genomic Health's ability to successfully commercially launch any such test; and the timing and amount of any future milestone or royalty payments. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to, the results of clinical studies; the applicability of clinical study results to actual outcomes; the risks and potential delays associated with such studies; the risks, costs and potential delays associated with the commercialization of a potential new test for anthracycline benefit; unanticipated costs or delays in research and development efforts; risks and uncertainties associated with the regulation of and reimbursement for the company's tests, both domestically and abroad; and the other risks set forth in the Genomic Health's filings with the Securities and Exchange Commission, including the risks set forth in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2013. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.


  Add GHDX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for GHDX - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.